{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T21:04:10Z","timestamp":1789419850232,"version":"build-2803163510"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2020,10,17]],"date-time":"2020-10-17T00:00:00Z","timestamp":1602892800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,10,17]],"date-time":"2020-10-17T00:00:00Z","timestamp":1602892800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1007\/s10067-020-05442-4","type":"journal-article","created":{"date-parts":[[2020,10,17]],"date-time":"2020-10-17T00:02:22Z","timestamp":1602892942000},"page":"1725-1737","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Performance of Janus kinase inhibitors in psoriatic arthritis with axial involvement in indirect comparison with ankylosing spondylitis: a retrospective analysis from pooled data"],"prefix":"10.1007","volume":"40","author":[{"given":"Lin","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofang","family":"Ping","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weibin","family":"Xing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,10,17]]},"reference":[{"issue":"6","key":"5442_CR1","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1038\/s41584-018-0006-8","volume":"14","author":"J Feld","year":"2018","unstructured":"Feld J, Chandran V, Haroon N, Inman R, Gladman D (2018) Axial disease in psoriatic arthritis and ankylosing spondylitis: a critical comparison[J]. Nat Rev Rheumatol 14(6):363\u2013371","journal-title":"Nat Rev Rheumatol"},{"issue":"1","key":"5442_CR2","doi-asserted-by":"crossref","first-page":"65","DOI":"10.7861\/clinmedicine.17-1-65","volume":"17","author":"LC Coates","year":"2017","unstructured":"Coates LC, Helliwell PS (2017) Psoriatic arthritis: state of the art review[J]. Clin Med (Lond) 17(1):65\u201370","journal-title":"Clin Med (Lond)"},{"issue":"9","key":"5442_CR3","first-page":"1452","volume":"56","author":"H Jethwa","year":"2017","unstructured":"Jethwa H, Abraham S (2017) The evidence for microbiome manipulation in inflammatory arthritis[J]. Rheumatology (Oxford) 56(9):1452\u20131460","journal-title":"Rheumatology (Oxford)"},{"issue":"18","key":"5442_CR4","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.3748\/wjg.v25.i18.2162","volume":"25","author":"GE Fragoulis","year":"2019","unstructured":"Fragoulis GE, Liava C, Daoussis D, Akriviadis E, Garyfallos A, Dimitroulas T (2019) Inflammatory bowel diseases and spondyloarthropathies: from pathogenesis to treatment[J]. World J Gastroenterol 25(18):2162\u20132176","journal-title":"World J Gastroenterol"},{"key":"5442_CR5","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.clim.2019.02.001","volume":"202","author":"DE Furst","year":"2019","unstructured":"Furst DE, Belasco J, Louie JS (2019) Genetic and inflammatory factors associated with psoriatic arthritis: relevance to diagnosis and management[J]. Clin Immunol 202:59\u201375","journal-title":"Clin Immunol"},{"issue":"10136","key":"5442_CR6","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1016\/S0140-6736(18)30830-4","volume":"391","author":"DJ Veale","year":"2018","unstructured":"Veale DJ, Fearon U (2018) The pathogenesis of psoriatic arthritis[J]. Lancet 391(10136):2273\u20132284","journal-title":"Lancet"},{"issue":"1","key":"5442_CR7","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/annrheumdis-2017-211734","volume":"77","author":"JS Smolen","year":"2018","unstructured":"Smolen JS, Schols M, Braun J, Dougados M, FitzGerald O, Gladman DD, Kavanaugh A, Landewe R, Mease P, Sieper J, Stamm T, Wit M, Aletaha D, Baraliakos X, Betteridge N, Bosch F, Coates LC, Emery P, Gensler LS, Gossec L, Helliwell P, Jongkees M, Kvien TK, Inman RD, McInnes IB, Maccarone M, Machado PM, Molto A, Ogdie A, Poddubnyy D, Ritchlin C, Rudwaleit M, Tanew A, Thio B, Veale D, Vlam K, van der Heijde D (2018) Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force[J]. Ann Rheum Dis 77(1):3\u201317","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"5442_CR8","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1097\/ICU.0000000000000525","volume":"29","author":"G Jhaj","year":"2018","unstructured":"Jhaj G, Kopplin LJ (2018) Ocular features of the HLA-B27-positive seronegative spondyloarthropathies[J]. Curr Opin Ophthalmol 29(6):552\u2013557","journal-title":"Curr Opin Ophthalmol"},{"key":"5442_CR9","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.ejim.2016.06.005","volume":"33","author":"L Pasina","year":"2016","unstructured":"Pasina L, Casadei G, Nobili A (2016) Biological agents and biosimilars: essential information for the internist[J]. Eur J Intern Med 33:28\u201335","journal-title":"Eur J Intern Med"},{"key":"5442_CR10","doi-asserted-by":"crossref","first-page":"j1707","DOI":"10.1136\/bmj.j1707","volume":"357","author":"N Casadevall","year":"2017","unstructured":"Casadevall N, Flossmann O, Hunt D (2017) Evolution of biological agents: how established drugs can become less safe[J]. BMJ 357:j1707","journal-title":"BMJ"},{"issue":"5","key":"5442_CR11","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1007\/s10067-017-3537-5","volume":"36","author":"JR Maneiro","year":"2017","unstructured":"Maneiro JR, Souto A, Gomez-Reino JJ (2017) Impact of treatment with TNF antagonists on total cholesterol in patients with ankylosing spondylitis and psoriatic arthritis[J]. Clin Rheumatol 36(5):1167\u20131172","journal-title":"Clin Rheumatol"},{"issue":"3","key":"5442_CR12","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.berh.2019.01.014","volume":"32","author":"M Torgutalp","year":"2018","unstructured":"Torgutalp M, Poddubnyy D (2018) Emerging treatment options for spondyloarthritis[J]. Best Pract Res Clin Rheumatol 32(3):472\u2013484","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"3","key":"5442_CR13","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1177\/2040622317743486","volume":"9","author":"S Dubash","year":"2018","unstructured":"Dubash S, McGonagle D, Marzo-Ortega H (2018) New advances in the understanding and treatment of axial spondyloarthritis: from chance to choice[J]. Ther Adv Chronic Dis 9(3):77\u201387","journal-title":"Ther Adv Chronic Dis"},{"issue":"5","key":"5442_CR14","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s40265-017-0701-9","volume":"77","author":"S Banerjee","year":"2017","unstructured":"Banerjee S, Biehl A, Gadina M, Hasni S, Schwartz DM (2017) JAK-STAT signaling as a target for inflammatory and autoimmune diseases: current and future prospects[J]. Drugs 77(5):521\u2013546","journal-title":"Drugs"},{"key":"5442_CR15","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1146\/annurev-med-051113-024537","volume":"66","author":"JJ O'Shea","year":"2015","unstructured":"O'Shea JJ, Schwartz DM, Villarino AV, Gadina M, McInnes IB, Laurence A (2015) The JAK-STAT pathway: impact on human disease and therapeutic intervention[J]. Annu Rev Med 66:311\u2013328","journal-title":"Annu Rev Med"},{"issue":"2\u20133","key":"5442_CR16","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1159\/000475809","volume":"233","author":"T Jin","year":"2017","unstructured":"Jin T, Sun Z, Chen X, Wang Y, Li R, Ji S, Zhao Y (2017) Serum human beta-defensin-2 is a possible biomarker for monitoring response to JAK inhibitor in psoriasis patients[J]. Dermatology 233(2\u20133):164\u2013169","journal-title":"Dermatology"},{"issue":"4","key":"5442_CR17","doi-asserted-by":"crossref","first-page":"w205","DOI":"10.1093\/ofid\/ofw205","volume":"3","author":"F Marra","year":"2016","unstructured":"Marra F, Lo E, Kalashnikov V, Richardson K (2016) Risk of herpes zoster in individuals on biologics, disease-modifying antirheumatic drugs, and\/or corticosteroids for autoimmune diseases: a systematic review and meta-analysis[J]. Open Forum Infect Dis 3(4):w205","journal-title":"Open Forum Infect Dis"},{"key":"5442_CR18","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1053\/j.gastro.2020.01.001","volume":"158","author":"P Olivera","year":"2020","unstructured":"Olivera P, Lasa J, Bonovas S, Danese S, Peyrin-Biroulet L (2020) Safety of Janus kinase inhibitors in patients with inflammatory bowel diseases or other immune-mediated diseases: a systematic review and meta-analysis[J]. Gastroenterology 158:1554\u20131573.e12","journal-title":"Gastroenterology"},{"key":"5442_CR19","doi-asserted-by":"crossref","first-page":"g7647","DOI":"10.1136\/bmj.g7647","volume":"350","author":"L Shamseer","year":"2015","unstructured":"Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart LA (2015) Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation[J]. BMJ 350:g7647","journal-title":"BMJ"},{"issue":"16","key":"5442_CR20","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1056\/NEJMoa1615977","volume":"377","author":"D Gladman","year":"2017","unstructured":"Gladman D, Rigby W, Azevedo VF, Behrens F, Blanco R, Kaszuba A, Kudlacz E, Wang C, Menon S, Hendrikx T, Kanik KS (2017) Tofacitinib for psoriatic arthritis in patients with an inadequate response to TNF inhibitors[J]. N Engl J Med 377(16):1525\u20131536","journal-title":"N Engl J Med"},{"issue":"16","key":"5442_CR21","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1056\/NEJMoa1615975","volume":"377","author":"P Mease","year":"2017","unstructured":"Mease P, Hall S, FitzGerald O, van der Heijde D, Merola JF, Avila-Zapata F, Cieslak D, Graham D, Wang C, Menon S, Hendrikx T, Kanik KS (2017) Tofacitinib or adalimumab versus placebo for psoriatic arthritis[J]. N Engl J Med 377(16):1537\u20131550","journal-title":"N Engl J Med"},{"issue":"1","key":"5442_CR22","first-page":"e806","volume":"5","author":"V Strand","year":"2019","unstructured":"Strand V, de Vlam K, Covarrubias-Cobos JA, Mease PJ, Gladman DD, Graham D, Wang C, Cappelleri JC, Hendrikx T, Hsu MA (2019) Tofacitinib or adalimumab versus placebo: patient-reported outcomes from OPAL broaden-a phase III study of active psoriatic arthritis in patients with an inadequate response to conventional synthetic disease-modifying antirheumatic drugs[J]. RMD Open 5(1):e806","journal-title":"RMD Open"},{"issue":"10162","key":"5442_CR23","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1016\/S0140-6736(18)32483-8","volume":"392","author":"P Mease","year":"2018","unstructured":"Mease P, Coates LC, Helliwell PS, Stanislavchuk M, Rychlewska-Hanczewska A, Dudek A, Abi-Saab W, Tasset C, Meuleners L, Harrison P, Besuyen R, Van der Aa A, Mozaffarian N, Greer JM, Kunder R, Van den Bosch F, Gladman DD (2018) Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial[J]. Lancet 392(10162):2367\u20132377","journal-title":"Lancet"},{"issue":"1","key":"5442_CR24","first-page":"e808","volume":"5","author":"V Strand","year":"2019","unstructured":"Strand V, de Vlam K, Covarrubias-Cobos JA, Mease PJ, Gladman DD, Chen L, Kudlacz E, Wu J, Cappelleri JC, Hendrikx T, Hsu MA (2019) Effect of tofacitinib on patient-reported outcomes in patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors in the phase III, randomised controlled trial: OPAL beyond[J]. RMD Open 5(1):e808","journal-title":"RMD Open"},{"issue":"8","key":"5442_CR25","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1136\/annrheumdis-2016-210322","volume":"76","author":"D van der Heijde","year":"2017","unstructured":"van der Heijde D, Deodhar A, Wei JC, Drescher E, Fleishaker D, Hendrikx T, Li D, Menon S, Kanik KS (2017) Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controlled, dose-ranging study[J]. Ann Rheum Dis 76(8):1340\u20131347","journal-title":"Ann Rheum Dis"},{"issue":"10162","key":"5442_CR26","doi-asserted-by":"crossref","first-page":"2378","DOI":"10.1016\/S0140-6736(18)32463-2","volume":"392","author":"D van der Heijde","year":"2018","unstructured":"van der Heijde D, Baraliakos X, Gensler LS, Maksymowych WP, Tseluyko V, Nadashkevich O, Abi-Saab W, Tasset C, Meuleners L, Besuyen R, Hendrikx T, Mozaffarian N, Liu K, Greer JM, Deodhar A, Landewe R (2018) Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trial[J]. Lancet 392(10162):2378\u20132387","journal-title":"Lancet"},{"issue":"8","key":"5442_CR27","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1093\/rheumatology\/key104","volume":"57","author":"WP Maksymowych","year":"2018","unstructured":"Maksymowych WP, van der Heijde D, Baraliakos X, Deodhar A, Sherlock SP, Li D, Fleishaker D, Hendrikx T, Kanik KS (2018) Tofacitinib is associated with attainment of the minimally important reduction in axial magnetic resonance imaging inflammation in ankylosing spondylitis patients[J]. Rheumatology (Oxford) 57(8):1390\u20131399","journal-title":"Rheumatology (Oxford)"},{"issue":"10214","key":"5442_CR28","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1016\/S0140-6736(19)32534-6","volume":"394","author":"D van der Heijde","year":"2019","unstructured":"van der Heijde D, Song IH, Pangan AL, Deodhar A, van den Bosch F, Maksymowych WP, Kim TH, Kishimoto M, Everding A, Sui Y, Wang X, Chu AD, Sieper J (2019) Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2\/3 trial[J]. Lancet 394(10214):2108\u20132117","journal-title":"Lancet"},{"issue":"8","key":"5442_CR29","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1111\/1346-8138.13258","volume":"43","author":"A Asahina","year":"2016","unstructured":"Asahina A, Etoh T, Igarashi A, Imafuku S, Saeki H, Shibasaki Y, Tomochika Y, Toyoizumi S, Nagaoka M, Ohtsuki M (2016) Oral tofacitinib efficacy, safety and tolerability in Japanese patients with moderate to severe plaque psoriasis and psoriatic arthritis: a randomized, double-blind, phase 3 study[J]. J Dermatol 43(8):869\u2013880","journal-title":"J Dermatol"},{"issue":"1","key":"5442_CR30","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1186\/s13075-018-1739-0","volume":"20","author":"P Helliwell","year":"2018","unstructured":"Helliwell P, Coates LC, FitzGerald O, Nash P, Soriano ER, Elaine HM, Hsu MA, Kanik KS, Hendrikx T, Wu J, Kudlacz E (2018) Disease-specific composite measures for psoriatic arthritis are highly responsive to a Janus kinase inhibitor treatment that targets multiple domains of disease[J]. Arthritis Res Ther 20(1):242","journal-title":"Arthritis Res Ther"},{"issue":"4","key":"5442_CR31","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.jaad.2016.12.004","volume":"76","author":"R Shreberk-Hassidim","year":"2017","unstructured":"Shreberk-Hassidim R, Ramot Y, Zlotogorski A (2017) Janus kinase inhibitors in dermatology: a systematic review[J]. J Am Acad Dermatol 76(4):745\u2013753","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"5442_CR32","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.jaad.2018.04.018","volume":"79","author":"AM Hosking","year":"2018","unstructured":"Hosking AM, Juhasz M, Mesinkovska NA (2018) Topical Janus kinase inhibitors: a review of applications in dermatology[J]. J Am Acad Dermatol 79(3):535\u2013544","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"5442_CR33","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.jaad.2016.12.005","volume":"76","author":"W Damsky","year":"2017","unstructured":"Damsky W, King BA (2017) JAK inhibitors in dermatology: the promise of a new drug class[J]. J Am Acad Dermatol 76(4):736\u2013744","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"5442_CR34","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s40259-019-00333-w","volume":"33","author":"TA Virtanen","year":"2019","unstructured":"Virtanen TA, Haikarainen T, Raivola J, Silvennoinen O (2019) Selective JAKinibs: prospects in inflammatory and autoimmune diseases[J]. BioDrugs 33(1):15\u201332","journal-title":"BioDrugs"},{"issue":"11","key":"5442_CR35","doi-asserted-by":"crossref","first-page":"102390","DOI":"10.1016\/j.autrev.2019.102390","volume":"18","author":"Y Jamilloux","year":"2019","unstructured":"Jamilloux Y, El JT, Vuitton L, Gerfaud-Valentin M, Kerever S, Seve P (2019) JAK inhibitors for the treatment of autoimmune and inflammatory diseases[J]. Autoimmun Rev 18(11):102390","journal-title":"Autoimmun Rev"},{"issue":"2","key":"5442_CR36","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.cyto.2013.04.027","volume":"63","author":"A Zgheib","year":"2013","unstructured":"Zgheib A, Pelletier-Bonnier E, Levros LJ, Annabi B (2013) Selective JAK\/STAT3 signalling regulates transcription of colony stimulating factor-2 and -3 in Concanavalin-A-activated mesenchymal stromal cells[J]. Cytokine 63(2):187\u2013193","journal-title":"Cytokine"},{"key":"5442_CR37","doi-asserted-by":"crossref","first-page":"212595","DOI":"10.7573\/dic.212595","volume":"8","author":"M Biggioggero","year":"2019","unstructured":"Biggioggero M, Becciolini A, Crotti C, Agape E, Favalli EG (2019) Upadacitinib and filgotinib: the role of JAK1 selective inhibition in the treatment of rheumatoid arthritis[J]. Drugs Context 8:212595","journal-title":"Drugs Context"},{"key":"5442_CR38","doi-asserted-by":"crossref","first-page":"104392","DOI":"10.1016\/j.phrs.2019.104392","volume":"147","author":"K Bechman","year":"2019","unstructured":"Bechman K, Yates M, Galloway JB (2019) The new entries in the therapeutic armamentarium: the small molecule JAK inhibitors[J]. Pharmacol Res 147:104392","journal-title":"Pharmacol Res"},{"issue":"2","key":"5442_CR39","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.jaad.2017.03.023","volume":"77","author":"KL Winthrop","year":"2017","unstructured":"Winthrop KL, Lebwohl M, Cohen AD, Weinberg JM, Tyring SK, Rottinghaus ST, Gupta P, Ito K, Tan H, Kaur M, Egeberg A, Mallbris L, Valdez H (2017) Herpes zoster in psoriasis patients treated with tofacitinib[J]. J Am Acad Dermatol 77(2):302\u2013309","journal-title":"J Am Acad Dermatol"},{"issue":"10","key":"5442_CR40","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1093\/ibd\/izy150","volume":"24","author":"JF Colombel","year":"2018","unstructured":"Colombel JF (2018) Herpes zoster in patients receiving JAK inhibitors for ulcerative colitis: mechanism, epidemiology, management, and prevention[J]. Inflamm Bowel Dis 24(10):2173\u20132182","journal-title":"Inflamm Bowel Dis"},{"issue":"10","key":"5442_CR41","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1093\/rheumatology\/kez087","volume":"58","author":"K Bechman","year":"2019","unstructured":"Bechman K, Subesinghe S, Norton S, Atzeni F, Galli M, Cope AP, Winthrop KL, Galloway JB (2019) A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis[J]. Rheumatology (Oxford) 58(10):1755\u20131766","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"5442_CR42","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1093\/rheumatology\/key339","volume":"58","author":"EH Choy","year":"2019","unstructured":"Choy EH (2019) Clinical significance of Janus kinase inhibitor selectivity[J]. Rheumatology (Oxford) 58(6):953\u2013962","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"5442_CR43","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.berh.2019.01.002","volume":"32","author":"JW Liew","year":"2018","unstructured":"Liew JW, Ramiro S, Gensler LS (2018) Cardiovascular morbidity and mortality in ankylosing spondylitis and psoriatic arthritis[J]. Best Pract Res Clin Rheumatol 32(3):369\u2013389","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"3","key":"5442_CR44","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1097\/BOR.0b013e32835fd8d5","volume":"25","author":"P Mease","year":"2013","unstructured":"Mease P (2013) Psoriatic arthritis and spondyloarthritis assessment and management update[J]. Curr Opin Rheumatol 25(3):287\u2013296","journal-title":"Curr Opin Rheumatol"},{"issue":"5","key":"5442_CR45","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.berh.2014.10.019","volume":"28","author":"F Van den Bosch","year":"2014","unstructured":"Van den Bosch F, Deodhar A (2014) Treatment of spondyloarthritis beyond TNF-alpha blockade[J]. Best Pract Res Clin Rheumatol 28(5):819\u2013827","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"12","key":"5442_CR46","doi-asserted-by":"crossref","first-page":"989","DOI":"10.2174\/1389201019666171226151852","volume":"18","author":"MM Luchetti","year":"2017","unstructured":"Luchetti MM, Benfaremo D, Gabrielli A (2017) Biologics in inflammatory and Immunomediated arthritis[J]. Curr Pharm Biotechnol 18(12):989\u20131007","journal-title":"Curr Pharm Biotechnol"},{"issue":"1","key":"5442_CR47","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/apt.15297","volume":"50","author":"C Ma","year":"2019","unstructured":"Ma C, Lee JK, Mitra AR, Teriaky A, Choudhary D, Nguyen TM, Vande CN, Khanna R, Panaccione R, Feagan BG, Jairath V (2019) Systematic review with meta-analysis: efficacy and safety of oral Janus kinase inhibitors for inflammatory bowel disease[J]. Aliment Pharmacol Ther 50(1):5\u201323","journal-title":"Aliment Pharmacol Ther"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-020-05442-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-020-05442-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-020-05442-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,17]],"date-time":"2021-10-17T01:39:35Z","timestamp":1634434775000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-020-05442-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,17]]},"references-count":47,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["5442"],"URL":"https:\/\/doi.org\/10.1007\/s10067-020-05442-4","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,17]]},"assertion":[{"value":"12 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 October 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"None.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}